Clinical Trials Browser

Terminated × Recurrence × elotuzumab × Clear all

NCT04150965 2025-02-14

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Phase 1/2 Terminated

Multiple Myeloma, Recurrence

NCT03023527 2018-05-23

Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma

Phase 1 Terminated

Multiple Myeloma, Recurrence